Skip to main content
. 2000 Dec 1;20(23):8846–8852. doi: 10.1523/JNEUROSCI.20-23-08846.2000

Fig. 5.

Fig. 5.

Pretreatment with the 5-HT2Cantagonist SB 206,553 does not attenuate DOI-elicited Fos expression in the SSC. SB 206,553 neither blunted the effect of DOI nor had any effect of its own. Abbreviations as in Figure 4, except that the pretreatment condition is SB 205,553 (SB). *p ≤ 0.005 relative to V-V.